4.6 Article

Studies to Assess the Utility of Serum Neurofilament Light Chain as a Biomarker in Chemotherapy-Induced Peripheral Neuropathy

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, Research & Experimental

Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy

Petra Huehnchen et al.

Summary: This study identifies neurofilament light chain (NFL) as a potential biomarker for chemotherapy-induced polyneuropathy (CIPN). In an in vitro model, NFL was released from sensory neurons treated with paclitaxel and showed an inverse correlation with cell viability. In a clinical study, NFL concentrations significantly increased in paclitaxel-treated patients with CIPN but not in patients receiving chemotherapy without CIPN or controls. This suggests that NFL could serve as a biomarker for early diagnosis of CIPN.

JCI INSIGHT (2022)

Article Clinical Neurology

Prospectively assessing serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity in breast cancer patients

Sofia Karteri et al.

Summary: This study assessed the significance of measuring serum neurofilament light chain levels as a biomarker of paclitaxel-induced peripheral neurotoxicity and found that sNfL levels can predict the development and severity of PIPN.

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2022)

Review Medicine, General & Internal

Types and Concentrations of Blood-Based Biomarkers in Adults With Peripheral Neuropathies: A Systematic Review and Meta-analysis

Joel Fundaun et al.

Summary: Neurofilament light chain is a reliable blood biomarker associated with peripheral neuropathy, according to this systematic review and meta-analysis of 36 studies.

JAMA NETWORK OPEN (2022)

Article Multidisciplinary Sciences

Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin

B. L. Burgess et al.

Summary: Management of chemotherapy-induced peripheral neuropathy (CIPN) is a significant challenge in cancer treatment. In this study, changes in serum levels of neurodegeneration markers NfL and GFAP were found to be associated with chemotherapy. Furthermore, changes in NfL levels predicted the onset and severity of CIPN, suggesting its potential as a predictive biomarker for dose-limiting CIPN.

SCIENTIFIC REPORTS (2022)

Article Clinical Neurology

Plasma NfL, clinical subtypes and motor progression in Parkinson's disease

Andrea Pilotto et al.

Summary: This study found that NfL levels were higher in PD patients compared to controls, with the high NfL group showing more severe symptoms, higher prevalence of malignant phenotype, and worse motor progression. Plasma NfL emerged as the best predictor of 2-year motor progression in PD.

PARKINSONISM & RELATED DISORDERS (2021)

Article Clinical Neurology

Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients

Chiara Pizzamiglio et al.

NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY (2020)

Article Clinical Neurology

Neurofilament light as a biomarker in traumatic brain injury

Pashtun Shahim et al.

NEUROLOGY (2020)

Review Biochemistry & Molecular Biology

Mechanisms of Chemotherapy-Induced Peripheral Neuropathy

Renata Zajaczkowska et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)

Review Clinical Neurology

Neurofilament light chain as a biomarker in neurological disorders

Lorenzo Gaetani et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2019)

Review Pharmacology & Pharmacy

Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity

Guido Cavaletti et al.

EXPERT OPINION ON PHARMACOTHERAPY (2018)

Article Clinical Neurology

Incidence and disease burden of chemotherapy-induced peripheral neuropathy in a population-based cohort

Arya Shah et al.

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)

Review Clinical Neurology

Neurofilaments as biomarkers in neurological disorders

Michael Khalil et al.

NATURE REVIEWS NEUROLOGY (2018)

Review Clinical Neurology

Chemotherapy-induced peripheral neuropathy clinical trials Review and recommendations

Jennifer S. Gewandter et al.

NEUROLOGY (2017)

Article Clinical Neurology

Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis

Giulio Disanto et al.

ANNALS OF NEUROLOGY (2017)

Article Psychology, Multidisciplinary

Repeated Measures Correlation

Jonathan Z. Bakdash et al.

FRONTIERS IN PSYCHOLOGY (2017)

Review Oncology

Chemotherapy-induced peripheral neuropathy: Current status and progress

Jamie R. Brewer et al.

GYNECOLOGIC ONCOLOGY (2016)

Review Clinical Neurology

Chemotherapy-induced peripheral neurotoxicity

Guido Cavaletti et al.

CURRENT OPINION IN NEUROLOGY (2015)

Article Clinical Neurology

Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab

Martin Gunnarsson et al.

ANNALS OF NEUROLOGY (2011)

Article Clinical Neurology

Evidence for Acute Neurotoxicity after Chemotherapy

Axel Petzold et al.

ANNALS OF NEUROLOGY (2010)

Article Clinical Neurology

Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity

G Cavaletti et al.

JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM (2006)